BASF Sweetens Takeover Offer for Evonik to €11 Billion as Shares Surge

Evonik Industries' executive board now holds the deciding vote on whether to accept a revised €11 billion takeover bid from BASF, with a formal response expected before the end of October 2026. The Essen-based specialty chemicals manufacturer must determine if the newly sweetened offer adequately values its high-margin additives portfolio.[1][2]

Shares in Evonik surged across European trading desks on Friday morning after reports of the increased bid surfaced. The stock climbed sharply as institutional investors signaled confidence that the €11 billion valuation bridges the pricing gap that stalled initial negotiations earlier in the year.[3][4]

The Ludwigshafen-based chemical giant is seeking to absorb Evonik to expand its footprint in the lucrative specialty chemicals sector. BASF’s revised proposal reportedly includes a higher cash component and stronger guarantees regarding the preservation of Evonik’s domestic workforce and manufacturing facilities.[1][5]

Financial analysts tracking the European materials sector note that the €11 billion figure represents a substantial premium over Evonik's undisturbed share price from September. This aggressive pricing strategy indicates BASF's urgency to secure the asset before rival multinational conglomerates can formulate competing bids.[2][6]

Strategic Pivot Toward Specialties

The European chemical sector has spent the period between 2024 and 2026 grappling with structural disadvantages, primarily driven by elevated regional energy costs. Consolidation has emerged as the primary mechanism for major manufacturers to protect profit margins and maintain global competitiveness against North American and Asian rivals.[2][6]

BASF’s strategic pivot toward high-margin, specialized products aligns directly with Evonik's established market dominance. Evonik currently controls significant global market share in animal nutrition supplements, smart materials, and active pharmaceutical ingredients, which offer far greater pricing power than traditional bulk petrochemicals.[1][3]

By acquiring Evonik, BASF would accelerate its transition away from energy-intensive basic chemicals. The €11 billion valuation reflects the premium required to secure immediate access to Evonik’s proprietary formulations and its extensive portfolio of patents in the personal care and cosmetics supply chain.[4][6]

The integration of Evonik's methionine production capabilities would be particularly transformative for BASF's agricultural division. Methionine, an essential amino acid used extensively in commercial poultry feed, remains one of Evonik's most profitable business units and a key driver of its consistent cash flow generation.[2][5]

Neither BASF chief executive Markus Kamieth nor Evonik's leadership team have issued public statements regarding the specific terms of the revised €11 billion proposal. Representatives for both chemical manufacturers declined to provide direct commentary on the ongoing negotiations when contacted by financial news outlets on Friday.[1][3]

Regulatory and Shareholder Hurdles

Any finalized agreement between the two German chemical heavyweights will face intense scrutiny from the European Commission's antitrust regulators in Brussels. The combined entity would command massive market share across several critical supply chains, prompting immediate concerns about pricing monopolies.[2][5]

Industry analysts anticipate that divestments in overlapping product lines will be a mandatory condition for regulatory approval. Portfolios involving construction chemicals, specific polymer additives, and agricultural chemical precursors are the most likely candidates to be spun off to satisfy European competition watchdogs.[3][6]

The regulatory review process for a transaction of this magnitude typically requires between twelve and eighteen months to complete. BASF's legal teams are likely already modeling various divestiture scenarios to present a proactive remedy package to the European Commission during the initial filing.[1][4]

The focus now shifts to Evonik's major shareholders, specifically the RAG-Stiftung, which holds a commanding stake in the enterprise. The foundation's mandate to finance the perpetual obligations of Germany's hard-coal mining industry means it requires reliable dividend yields or a substantial cash premium to exit its position.[1][4]

If the RAG-Stiftung determines that the €11 billion figure undervalues Evonik's long-term dividend potential, BASF will be forced to either walk away or attempt a hostile takeover. However, hostile bids remain exceptionally rare and structurally difficult to execute within the German corporate governance framework.[2][5]

Broader Market Implications

This transaction represents the largest proposed chemical industry merger since 2024, signaling a potential thaw in European dealmaking. Higher interest rates had previously suppressed major acquisitions, but stabilizing borrowing costs have allowed corporate development teams to model large-scale debt financing with greater certainty.[3][4]

Competitors across the specialty chemicals landscape are monitoring the BASF-Evonik negotiations closely. A successful €11 billion acquisition could trigger a wave of defensive mergers among mid-cap chemical producers in France, Switzerland, and the United Kingdom as they attempt to build sufficient scale to compete.[1][6]

The integration of Evonik would also require BASF to navigate complex labor negotiations with Germany's powerful industrial unions. Securing the support of worker representatives on both companies' supervisory boards is a legal prerequisite for finalizing the merger under the nation's co-determination laws.[2][5]

Labor leaders will demand binding guarantees that the merger will not result in forced redundancies at domestic production sites. BASF's willingness to offer these employment protections as part of the €11 billion package will be critical to preventing a protracted battle with the IG BCE chemical workers union.[3][6]

Evonik's management board is scheduled to convene next week to formally review the sweetened proposal alongside their financial advisors. The market will be watching for any signals regarding the board's willingness to grant BASF access to the confidential data room for formal due diligence.[3][4]

Until a definitive agreement is signed, Evonik remains an independent entity capable of soliciting alternative bids from private equity consortiums or other industrial buyers. However, the sheer scale of the €11 billion valuation makes the emergence of a credible counter-bidder highly improbable in the current economic environment.[1][5]